Consumer Analyst Group of New York Conference 2025
Logotype for International Flavors & Fragrances Inc

International Flavors & Fragrances (IFF) Consumer Analyst Group of New York Conference 2025 summary

Event summary combining transcript, slides, and related documents.

Logotype for International Flavors & Fragrances Inc

Consumer Analyst Group of New York Conference 2025 summary

8 Jul, 2026

Strategic overview and financial performance

  • Achieved $11.5 billion in 2024 sales and $2.2 billion in EBITDA, with a 19.2% EBITDA margin, reflecting strong top and bottom-line performance.

  • Business is highly diversified across Nourish, Health & Biosciences (H&B), Scent, and Pharma Solutions, with Pharma Solutions set to exit by Q2 2025.

  • 2024 saw 6% top-line growth, 16% comparable EBITDA growth, and 210 basis points of margin expansion.

  • Leverage improved from 4.4x to 3.8x, with a target to be below 3x net debt/EBITDA after Pharma Solutions divestiture and proceeds from recent divestitures.

  • Capital allocation focuses on capacity expansion, digital transformation, maintaining a consistent dividend, and potential share buybacks once leverage targets are met.

Innovation, R&D, and business unit strategies

  • Invests $671 million annually in R&D, representing 5.8% of sales, supporting 3,400 R&D employees, 8,000 patents, and 50+ research centers globally.

  • H&B business leverages biotech capabilities, growing mid-single digits with a 30% EBITDA margin.

  • Taste strategy targets increased penetration in private label and food service, with current private label share below 5%.

  • Digital transformation and AI are being deployed to enhance efficiency and margin expansion.

  • Business strategies for 2025 focus on independent business units, R&D leadership, digital acceleration, and cost structure transformation.

Biotech and Health & Biosciences focus

  • Biotech capability built from Genencor, Danisco, DuPont, and IFF, with over 5,500 bioscience patents.

  • Core technologies include enzymes, probiotics, and cultures, with a focus on discovery, scale, and application.

  • R&D reinvestment in H&B is about 9% of sales, supporting a robust pipeline and global leadership.

  • Recent innovations include TexStar enzymes for sugar-to-fiber conversion, next-gen anaerobic probiotics, and biodegradable polymers.

  • Bioscience platform leverages unique capabilities across taste, scent, food ingredients, and health, with a robust pipeline of innovations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from International Flavors & Fragrances